NEW YORK (360Dx) – Startup RenalytixAI has set its sights on the kidney disease diagnostic space with its blood-based assay, which it believes will help improve clinical management of patients with type 2 diabetes and individuals of African-American descent with fast-progressing kidney disease.

The London-based firm recently began a clinical validation study for its chronic kidney disease (CKD) diagnostic, KidneyIntelX, with intentions of seeking de novo 510(k) approval from the US Food and Drug Administration later this year.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.